| Cat. No. |
Product Name |
CAS No. |
Information |
| H9244 |
AKTide-2T TFA
|
|
AKTide-2T TFA is an excellent in vitro substrate for AKT and shows competitive inhibition of histone H2B phosphorylation with a Ki of 12 nM; AKTide-2T TFA mimics the optimal phosphorylation sequence of Akt and is an inhibitory peptide with the wildtype AKTide lacking Thr in the S22 position. |
| H9243 |
AKTide-2T
|
324029-01-8 |
AKTide-2T is an excellent in vitro substrate for AKT and shows competitive inhibition of histone H2B phosphorylation with a Ki of 12 nM; AKTide-2T mimics the optimal phosphorylation sequence of Akt and is an inhibitory peptide with the wildtype AKTide lacking Thr in the S22 position. |
| H6915 |
SC-79
|
305834-79-1 |
A unique specific Akt activator; binds to the PH domain of Akt and inhibits Akt membrane translocation, but paradoxically activates Akt in the cytosol; induces the p-Akt (Ser473) expression and significantly increases the expression of Bcl-2 and p-GSK-3β (Ser9), decreases the protein levels of Bax, cytoplasm cytochrome C, and cleaved caspase-3.; augments neuronal survival in mouse model for ischemic strok. |
| H6914 |
SC-66
|
871361-88-5 |
SC66 is an allosteric Akt inhibitor; exhibits a dual inhibitory activity that directly interferes with the PH domain binding to PIP3 and facilitates Akt ubiquitination; has anticancer activity mouse xenograft tumor model. |
| H6913 |
PHT-427
|
1191951-57-1 |
PHT-427 is a small-molecule Akt inhibitor that binds selectively to the PH domain of AKT with Ki of 2.4 uM, inhibits phospho-Ser473-AKT in Panc-1 cells with IC50 of 6.3 uM; decreases AKT activation and causes apoptosis at low micromolar concentrations in Panc-1 and MiaPaCa-2 pancreatic cancer cell lines; inhibits AKT and its downstream targets in cells, exhibits good antitumor activity in pancreatic cancer cell xenografts in immunocompromised mice. |
| H6912 |
Perifosine
|
157716-52-4 |
A oral bioavailable alkylphospholipid that displays significant antiproliferative activity in vitro and in vivo in several human tumor model; acts as an Akt inhibitor and a PI3K inhibitor, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway; enhances apoptosis and inhibits the growth of xenografts in nude mice combined with a lysosomal inhibitor. |
| H6911 |
MK 2206 dihydrochloride
|
1032350-13-2 |
A potent, orally active allosteric Akt inhibitor with IC50 of 5/12 nM for Akt1/Akt2 respectively; shows 5-fold less potent against human Akt3 (IC50=65 nM); synergistically inhibits cell proliferation of human cancer cell lines in combination with erlotinib or lapatinib in vitro; suppresses the Akt phosphorylation that is induced by carboplatin and gemcitabine. |
| H6910 |
Miransertib
|
1313881-70-7 |
Miransertib (ARQ-092) is a potent, selective and allosteric inhibitor of Akt1/2/3 with IC50 of 5/4.5/16 nM respectively; inhibits cellular AKT activation and the phosphorylation of the downstream target PRAS40; inhibits tumor growth in a human xenograft mouse model of endometrial adenocarcinoma; orally bioavailable. |
| H6908 |
GSK-690693
|
937174-76-0 |
A potent, ATP competitive, pan-AKT inhibitor with IC50 of 2, 13, and 9 nM against AKT1, 2, and 3, respectively; also inhibits additional members of the AGC kinase family (PKA, PrkX, and PKC isozymes, IC50s<100 nM); dose-dependently reduces the phosphorylation GSK3 beta, PRAS40 and Forkhead, inhibits proliferation and induces apoptosis in a subset of tumor cells; exhibits significant antitumor activity in mice model. |
| H6907 |
Ch-319
|
|
Ch-319 (Ch319) is a triphenyltin (IV) carboxylate derivative that modulates AKT/FOXO3a signaling and inhibits progression of prostate cancer; reduces viability and induces cell cycle arrest associated with downregulation of PI3K and dephosphorylation of AKT and PRAS40 in PTEN-null PC3M and DU145 PCa cells at 250-500 nM; decreases tumor weights, reduces expression of androgen receptor, decreases phosphorylation of AKT and PRAS40 and increases FOXO3a in mice. |
$ USD
Select Your Country or Region